Gold Is Precious—But a Potent Sensitizer?
Publication date: January 2019Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 7, Issue 1Author(s): Werner Aberer
Is it efficacious and cost-effective to continue aminosalicylates in patients with ulcerative colitis who have been escalated to immunosuppressants, biologics, or oral small molecules?Alimentary Pharmacology &Therapeutics
The treatment of community-acquired pneumonia has become increasingly challenging due to antibiotic resistance, but the availability of new agents may offer more options.Current Opinion in Infectious Diseases
This article provides an update for its use in children.Pediatric Pharmacotherapy
Publication date: Available online 15 March 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Brittany Esty, Hani Harb, Lisa M. Bartnikas, Louis M. Charbonnier, Amir H. Massoud, Carmen Leon-Astudillo, Gary Visner, Meera Subramaniam, Wanda Phipatanakul, Talal A. Chatila
Publication date: Available online 15 March 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Jose Luis Ramírez-Bellver, Ricardo Ruiz-Rodriguez, Ignacio Sanchez-Carpintero
Conclusion: When trimethoprim-sulfamethoxazole cannot be used because of resistance or allergy, tigecycline alone or in combination may be included as an alternative option. Although in vitro results are promising, clinical data are required. PMID: 30866602 [PubMed - as supplied by publisher]
This article will provide a compact overview about recent developments in this rapidly growing field in otorhinolaryngology which might establish the basis for promising therapeutic strategies for previously insufficiently treatable disorders of the head and neck. PMID: 30874856 [PubMed - as supplied by publisher]
This study provides a novel and detailed frame of reference of normal counts of different monocytic cell subsets in blood throughout life and highlights their differential distribution among distinct lymphoid tissues.
Conclusions: This is the first study to examine the efficacy of a CRTh2 antagonist in antihistamine-refractory CSU. AZD1981 treatment was well tolerated, effectively inhibited PGD2-mediated eosinophil shape change, shifted numbers of circulating eosinophils, and reduced weekly itch scores more than hives during treatment and into washout. Further studies are needed to determine whether inhibition of the PGD2/CRTh2 pathway will be an effective treatment for CSU.Int Arch Allergy Immunol
Conclusions: Triamcinolone acetonide proved to be non-inferior to fluticasone propionate in adult patients with PAR; both treatments decreased rTNSS values and showed a good safety profile.Int Arch Allergy Immunol